Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  New England Journal of Medicine

• Publication date

  2001-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM200102013440501PMID 11172162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination

  2005cited by this paper
• [The first episode of central nervous system demyelinization and hepatitis B virus vaccination].

  2000cited by this paper
• Evaluation of surgery for Parkinson's disease: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  2000cited by this paper
• School-based hepatitis B vaccination programme and adolescent multiple sclerosis.

  2000cited by this paper
• No increase in demyelinating diseases after hepatitis B vaccination

  1999cited by this paper
• Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.

  1999cited by this paper
• Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

  1999cited by this paper
• Rate of Pregnancy-Related Relapse in Multiple Sclerosis

  1998cited by this paper
• Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

  1998cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis

  1997cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Neuropapillite bilatérale avec décollement séreux du neuroépithélium, au décours d'une vaccination contre l'hépatite B

  1996cited by this paper
• [Acute myelitis after immunization against hepatitis B with recombinant vaccine].

  1996cited by this paper
• Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System.

  1996cited by this paper
• Risk of cancer from azathioprine therapy in multiple sclerosis

  1996cited by this paper
• MR imaging in a case of postvaccination myelitis.

  1995cited by this paper
• Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination

  1995cited by this paper
• Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype.

  1995cited by this paper
• [Acute myelitis after vaccination against hepatitis B].

  1993cited by this paper
• Transverse myelitis following hepatitis B vaccination.

  1993cited by this paper
• Multiple sclerosis and hepatitis B vaccination.

  1993cited by this paper
• Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons.

  1992cited by this paper
• EDMUS, a European database for multiple sclerosis.

  1992cited by this paper
• Adverse events after hepatitis B vaccination.

  1992cited by this paper
• Vaccination of patients with encephalomyelitis disseminata.

  1991cited by this paper
• The case-crossover design: a method for studying transient effects on the risk of acute events.

  1991cited by this paper
• Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine.

  1991cited by this paper
• Das mögliche Risiko von Impfungen für die Erstmanifestation der multiplen Sklerose* **

  1990cited by this paper
• Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination.

  1990cited by this paper
• The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children

  1989cited by this paper
• Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years.

  1988cited by this paper
• Postvaccinal neurological complication: report of 12 cases

  1984cited by this paper
• Swine flu vaccine and multiple sclerosis.

  1984cited by this paper
• Postvaccinal neurological complication. Report of 12 cases.

  1984cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Swine-influenza vaccine.

  1982cited by this paper
• Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

  1980cited by this paper
• Swine influenza vaccination in patients with multiple sclerosis.

  1978cited by this paper
• Swine influenza virus vaccination in patients with multiple sclerosis.

  1977cited by this paper
• Influenza vaccination in patients with multiple sclerosis.

  1976cited by this paper
• A PROSPECTIVE STUDY of PARAPARESES IN WESTERN SWEDEN

  1976cited by this paper
• Relapsing encephalomyelitis following the use of influenza vaccine.

  1972cited by this paper
• Immune status of patients with multiple sclerosis

  1972cited by this paper
• Multiple sclerosis and vaccination.

  1967cited by this paper
• Disseminated sclerosis syndrome following antirabic vaccination.

  1967cited by this paper
• [Antidiphtheria vaccination as a factor precipitating multiple sclerosis].

  1966cited by this paper
• INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS *

  1965cited by this paper
• The possible role of vaccines and sera in the pathogenesis of multiple sclerosis.

  1961cited by this paper

• Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study

  2025cites this paper
• Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization

  2025cites this paper
• Efficacy of Carbopol as an Adjuvant for Inactivated Rift Valley Fever Vaccine

  2025cites this paper
• Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

  2025cites this paper
• Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

  2024cites this paper
• Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France

  2024cites this paper
• Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?

  2024cites this paper
• Impfen in schwierigen Situationen

  2024cites this paper
• Vaccination contre l’hépatite B

  2024cites this paper
• Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

  2024cites this paper
• COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

  2023cites this paper
• Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

  2023cites this paper
• Vaccination frequency in people newly diagnosed with multiple sclerosis

  2023cites this paper
• [Association between vaccination and the risk of immunoglobulin A vasculitis in children].

  2023cites this paper
• A Review for Vaccination Guidelines in Patients with Central Nervous System Demyelinating Diseases including COVID-19 Vaccination

  2023cites this paper
• Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study

  2023cites this paper
• European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

  2023influential citation
• Vaccination in Individuals with Multiple Sclerosis – Part I

  2023cites this paper
• Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups.

  2023cites this paper
• ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

  2023cites this paper
• Risk of disease relapse, safety and tolerability of SARS‐CoV‐2 vaccination in patients with chronic inflammatory neuropathies

  2023cites this paper
• Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.

  2023cites this paper
• Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?

  2022cites this paper
• Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis

  2022cites this paper
• To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection

  2022cites this paper
• Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study

  2022cites this paper
• Vaccination and Multiple Sclerosis – Current Situation

  2022cites this paper
• Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review

  2022cites this paper
• Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

  2022cites this paper
• Hepatitis B Vaccination: A Historical Overview with a Focus on the Italian Achievements

  2022cites this paper
• Recent advances of chitosan-based nanoparticles for biomedical and biotechnological applications.

  2022cites this paper
• Impfungen bei Störungen der Immunfunktion

  2022cites this paper
• There Is No Evidence That Inactivated COVID-19 Vaccines Increase Risks of Uveitis Flare

  2022cites this paper
• Evaluation of the Toxic Effects of Aluminum Hydroxide Nanoparticles as Adjuvants in Vaccinated Neonatal Mice.

  2022cites this paper
• Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity

  2022cites this paper
• Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

  2021cites this paper
• Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?

  2021cites this paper
• Neurologic Diseases

  2021cites this paper
• Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

  2021cites this paper
• Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

  2021cites this paper
• Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses

  2021cites this paper
• A small but significantly greater incidence of inflammatory heart disease identified after vaccination for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)

  2021cites this paper
• Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection

  2021cites this paper
• [Vaccination and multiple sclerosis at the present stage].

  2021cites this paper
• EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

  2021cites this paper
• Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization

  2021cites this paper
• Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?

  2021cites this paper
• Acute and chronic inflammatory neuropathies and COVID‐19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)

  2021cites this paper
• Vaccinations and Autoimmune Diseases

  2021cites this paper
• COVID-19 mRNA vaccination leading to CNS inflammation: a case series

  2021cites this paper
• Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

  2021cites this paper
• Interpretation of vaccine associated neurological adverse events: a methodological and historical review

  2021cites this paper
• Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien

  2021cites this paper
• Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

  2021cites this paper
• High-salt diet suppresses autoimmune demyelination by regulating the blood–brain barrier permeability

  2021cites this paper
• A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2

  2021cites this paper
• Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

  2020cites this paper
• Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis.

  2020cites this paper
• A systematic review and meta-analysis

  2020cites this paper
• Factors associated with relapses in relapsing-remitting multiple sclerosis

  2020cites this paper
• Guías de práctica para indicación y contraindicaciones de vacunación de pacientes con esclerosis múltiple

  2020cites this paper
• Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia

  2020cites this paper
• Vaccination in multiple sclerosis - Challenging practices (Review).

  2020cites this paper
• Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic Disorders During the COVID-19 Pandemic

  2020cites this paper
• Ist komplette Immunität gegen Masern bei Patienten mit rheumatischen Erkrankungen ein realistisches Ziel, und wie ist es möglicherweise zu erreichen?

  2020cites this paper
• Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement.

  2020cites this paper
• Protecting people with multiple sclerosis through vaccination

  2020cites this paper
• [Is complete immunity against measles a realistic target for patients with rheumatic diseases and how can it possibly be achieved?]

  2020cites this paper
• Effects of MS disease-modifying therapies on responses to vaccinations: A review.

  2020cites this paper
• Impfen bei Primären Immundefekten, Autoimmunkrankheiten und anderen chronisch entzündlichen Erkrankungen unter immunmodulatorischer Therapie

  2020cites this paper
• Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine

  2020cites this paper
• Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion

  2020cites this paper
• Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective

  2020cites this paper
• Vaccination in Multiple Sclerosis: Friend or Foe?

  2019cites this paper
• Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain

  2019cites this paper
• Principal Controversies in Vaccine Safety in the United States.

  2019cites this paper
• Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision‐making

  2019cites this paper
• Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society.

  2019cites this paper
• Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination

  2019cites this paper
• Impfen bei Immundefizienz

  2019cites this paper
• Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.

  2019cites this paper
• Vaccine hesitancy ‘outbreaks’: using epidemiological modeling of the spread of ideas to understand the effects of vaccine related events on vaccine hesitancy

  2018cites this paper
• Do Vaccines Cause Multiple Sclerosis (MS)

  2018cites this paper
• 213 – Hepatitis B and Hepatitis D Viruses

  2018cites this paper
• Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis.

  2018cites this paper
• Vaccination and Risk of Childhood IgA Vasculitis

  2018cites this paper
• 83 – Legal Issues

  2018cites this paper
• Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies

  2018cites this paper
• Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

  2018cites this paper
• Vaccines and immunotherapies

  2018cites this paper
• Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada

  2018cites this paper
• Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to 'autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA).

  2018cites this paper
• The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience

  2017cites this paper
• Hepatitis B vaccination status in an at-risk adult population: long-term immunity but insufficient coverage

  2017cites this paper
• Characteristics of pediatric multiple sclerosis: The Turkish pediatric multiple sclerosis database.

  2017cites this paper
• Vaccines and multiple sclerosis: a systematic review

  2017cites this paper
• Hepatitis B and D

  2017cites this paper
• Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

  2017cites this paper
• The Association of Specific Constituents of the Fecal Microbiota with Immune-Mediated Brain Disease in Dogs

  2017cites this paper
• Infections of the Central Nervous System in Returning Travelers and Immigrants

  2017cites this paper